{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:54:16Z","timestamp":1791057256076,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-22-1-0067"],"award-info":[{"award-number":["W81XWH-22-1-0067"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urology.2026.06.027","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:13:04Z","timestamp":1782313984000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrative Genomic Profiling of Newly Diagnosed Prostate Cancers Progressing on Surveillance"],"prefix":"10.1016","volume":"215","author":[{"given":"Nichelle C.","family":"Whitlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Y.","family":"Trostel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chennan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosina T.","family":"Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Terrigino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy D.","family":"Vocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.06.027_bib1","first-page":"583","article-title":"NCCN guidelines updates: management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.06.027_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.06.027_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2020.06.041","article-title":"Serial molecular profiling of low-grade prostate cancer to assess tumor upgrading: a longitudinal cohort study","volume":"79","author":"Salami","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00345-021-03622-8","article-title":"Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes","volume":"40","author":"Walker","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2026.06.027_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.06.027_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.06.027_bib9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib10","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.22262","article-title":"Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy","volume":"107","author":"Cooperberg","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.06.027_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.afju.2015.09.009","article-title":"Accuracy of the contemporary Epstein criteria to predict insignificant prostate cancer in North African Man","volume":"22","author":"Ammani","year":"2016","journal-title":"Afr J Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"21","key":"10.1016\/j.urology.2026.06.027_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123468","article-title":"Transcriptomic heterogeneity in multifocal prostate cancer","volume":"3","author":"Salami","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.urology.2026.06.027_bib14","article-title":"Prognostic value of genomic classifier testing for prostate cancer: a systematic review","author":"Boyer","year":"2023","journal-title":"VA Evidence-Based Synthesis Program Reports"},{"key":"10.1016\/j.urology.2026.06.027_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.06.027_bib16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urology.2026.06.027_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.urology.2026.06.027_bib18","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/1078-0432.CCR-16-2414","article-title":"Gleason score 7 prostate cancers emerge through branched evolution of clonal gleason pattern 3 and 4","volume":"23","author":"Sowalsky","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2026.06.027_bib19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","article-title":"The proteogenomic landscape of curable prostate cancer","volume":"35","author":"Sinha","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urology.2026.06.027_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/0008-5472.CAN-12-2799","article-title":"Clonal progression of prostate cancers from gleason Grade 3 to Grade 4","volume":"73","author":"Sowalsky","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2026.06.027_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12943-020-01264-9","article-title":"Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing","volume":"19","author":"Ma","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.urology.2026.06.027_bib22","unstructured":"Tissue expression of FLNA gene (ENSG00000196924). The Human Protein Atlas"},{"key":"10.1016\/j.urology.2026.06.027_bib23","unstructured":"Tissue expression of LPP gene (ENSG00000145012). The Human Protein Atlas"},{"key":"10.1016\/j.urology.2026.06.027_bib24","unstructured":"Tissue expression of SPEG gene (ENSG00000072195). The Human Protein Atlas"},{"key":"10.1016\/j.urology.2026.06.027_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PAS.0b013e318206b67b","article-title":"ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma","volume":"35","author":"Miettinen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urology.2026.06.027_bib26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-16-1454","article-title":"Molecular profiling to determine clonality of serial magnetic resonance imaging\/ultrasound fusion biopsies from men on active surveillance for low-risk prostate cancer","volume":"23","author":"Palapattu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2026.06.027_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111404","article-title":"FOXA1 regulates alternative splicing in prostate cancer","volume":"40","author":"Del Giudice","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.urology.2026.06.027_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.21873\/invivo.14197","article-title":"FOXA1 alterations in prostate cancer: expression, mutation classes, and copy number changes","volume":"40","author":"Lehrer","year":"2026","journal-title":"In Vivo"},{"key":"10.1016\/j.urology.2026.06.027_bib29","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/2767-9764.CRC-24-0210","article-title":"Prostate cancer progression modeling provides insight into dynamic molecular changes associated with progressive disease states","volume":"4","author":"Chen","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.urology.2026.06.027_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015575125780","article-title":"Chromosomal deletions and tumor suppressor genes in prostate cancer","volume":"20","author":"Dong","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.urology.2026.06.027_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.urology.2026.06.027_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tcb.2018.03.001","article-title":"Crosstalk between YAP\/TAZ and Notch signaling","volume":"28","author":"Totaro","year":"2018","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.urology.2026.06.027_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.urology.2026.06.027_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urology.2026.06.027_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.euf.2018.01.006","article-title":"Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy","volume":"5","author":"VanderWeele","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2026.06.027_bib36","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.urology.2026.06.027_bib37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.eururo.2021.03.009","article-title":"Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy","volume":"80","author":"Wilkinson","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.06.027_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.urology.2026.06.027_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s43018-023-00533-y","article-title":"Inferring early genetic progression in cancers with unobtainable premalignant disease","volume":"4","author":"Leshchiner","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.urology.2026.06.027_bib40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526004152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526004152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:36:25Z","timestamp":1791056185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526004152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0090429526004152"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.06.027","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative Genomic Profiling of Newly Diagnosed Prostate Cancers Progressing on Surveillance","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}